tradingkey.logo

Neurosense Confirms Favorable Safety And Tolerability Of Primec In An Alzheimer's Phase 2 Study

ReutersDec 22, 2025 2:20 PM

- Neurosense Therapeutics Ltd NRSN.O:

  • NEUROSENSE CONFIRMS FAVORABLE SAFETY AND TOLERABILITY OF PRIMEC IN AN ALZHEIMER'S PHASE 2 STUDY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI